Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of acalabrutinib in relapsed or refractory chronic lymphocytic leukemia intolerant to ibrutinib
MOH_2017-02-02_000085Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Acerta Pharma. Primary endpoint: Primary efficacy endpoint. Started Jul 2016; status: completed.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-02-02_000085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-02_000085.